This study looks at a new medicine called CVN424 for people with early Parkinson's Disease (PD). Parkinson's is a condition that affects movement. The study lasts for 12 weeks and compares CVN424 with a placebo (a pill that looks like the medicine but has no active ingredients). The goal is to see if CVN424 helps with movement and other symptoms without using other PD medicines.

To join, you must have been diagnosed with PD, not be on any PD medicines, and expect not to need them during the study. You should be at least 30 years old and able to walk. Women who can have children and men with partners who can have children must agree to use birth control during the study. You also need to agree to visit the study center and follow instructions.

• The study lasts about 3 months with regular check-ups.
• Participants will take CVN424 or a placebo daily.
• The study checks how CVN424 affects movement and symptoms.

If you have other health issues like certain heart conditions or have been using certain medicines, you may not be able to join. Participants should not be pregnant, using recreational drugs, or involved in another drug study. The study requires a negative COVID-19 test.